Jo El J. Schultz , PHD

Doctoral Degree: Medical College of Wisconsin Milwaukee, WI, 1997 (Cardiovascular Pharmacology)

Bachelor's Degree : University of Wisconsin- Stevens Point Stevens Point, WI, 1991 (Biology; minored in Chemistry and French)

Postdoctoral Assistant: University of Cincinnati Cincinnati, OH, 2000 (Biochemistry, and Microbiology)

Research Assistant: Medical College of Wisconsin Milwaukee, WI, 1993

Research technician: Medical College of Wisconsin Milwaukee, WI, 1990 (Anesthesiology )

Volunteer research technician: Medical College of Wisconsin Milwaukee, WI, 1990 (Milwaukee, WI)

The interests of my research program are to elucidate the signaling mechanisms involved in cardiac pathophysiology, especially in relation to cardioprotection (heart protecting itself against injury due to ischemia) and heart failure. Our approach involves the utilization of transgenic and gene-targeted mice with pertubations of specific receptors, endogenous factors, and signal transduction cascades in the heart. This allows us to relate changes in the action of single gene products with specific alterations of cardiac biochemistry, physiology and pathophysiology in vivo. Both in vivo and in vitro physiological approaches are utilized in my lab to elucidate the contribution of the opioid and growth factor receptor systems to cardiac pathophysiology. We routinely employ echocardiography, work-performing and Langendorff whole heart preparations, in vivo hemodynamic measurements, and isolation and analysis of cardiomyocytes. In addition, a number of surgical techniques (aortic banding, coronary artery ligation, catheterizations) are used in my laboratory. Throughout these studies, pharmacological, histological, biochemical, and state-of-the art molecular biology assays are employed, and include PCR for mouse genotype determination, Northern blot and quantitative real-time PCR analysis of mRNA expression, and protein analysis via Western blot, ELISA and immunostaining. Genomic and proteomic tools, including DNA microarrays, will be implemented in the lab to further characterize or identify known and novel mechanism(s) of opioid- and growth factor-mediated cardiovascular physiology and pathology.

09-2007 -To Present Associate Professor, Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, Cincinnati, OH

01-2001 -08-2007 Assistant Professor, Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, Cincinnati, OH

01-2001 -06-2005 Director, Isolated Work-Performing Heart Facility Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, Cincinnati, OH

Investigators:J.J. Schultz 01-01-1996 -12-31-1997 Pharmaceutical Research and Manufacturers of America, Inc. Foundation “A Role of Opioid Receptors in Ischemic Preconditioning in the Rat Heart” Role:PI

Investigators:J.J. Schultz 01-01-2002 -12-31-2003 Pharmaceutical Research and Manufacturers of America Foundation “Role of protein kinases in fibroblast growth factor-2-induced cardioprotection” Role:PI

Grant: #R01, 1 R01 HL70174 Investigators:T. Doetschman, J.J. Schultz 04-01-2002 -03-31-2006 National Institute of Heart, Lung, and Blood “Roles of FGF2 and TGFbeta1 in cardiac hypertrophy” Role:Co-PI

Grant: #RFA, 5 U24 DK059630 Investigators:P. Tso, J.J. Schultz 07-01-2001 -06-30-2006 National Institute of Diabetes and Digestive and Kidney Diseases “Cincinnati Mouse Diabetes Phenotype Center” Role:Co-PI

Grant: #R01, 1 R01 HL075633 Investigators:J.J. Schultz 07-01-2004 -06-30-2008 National Institute of Heart, Lung, and Blood “Signaling mechanisms of FGF2-induced cardioprotection” Role:PI

Investigators:J.J. Schultz 11-09-2007 -11-09-2008 Dean’s Bridge Funding “Role of the Opioidergic System in the Development of Heart Failure” Role:PI

Grant: #R21, 1 R21 DA0804 Investigators:J.J. Schultz 04-01-2008 -03-31-2010 National Institute of Drug Abuse “Role of the Opioidergic System in the Development of Heart Failure” Role:PI

Investigators:D.A. Pietras, J.J. Schultz 04-01-2008 -03-31-2009 American Medical Association Seed Grant “Identifying Downstream Molecular Targets of FGF2-Induced Cardioprotection” Role:Sponsor

Investigators:J.J. Schultz 06-01-2007 National Institute of Health, National Heart, Lung, and Blood “Fibroblast growth factor-2 isoforms in cardiac ischemia” Role:PI

Grant: #1 R01 HL075633 Investigators:J.J. Schultz 11-01-2007 National Institute of Heart, Lung, and Blood “Signaling mechanisms of FGF2-induced cardioprotection” Role:PI

Grant: #uc Investigators:Schultz, Jo El 07-01-2004 -06-30-2010 National Heart, Lung and Blood Institute Signaling Mechanisms of FGF2-induced Cardioprotection Role:PI $1,485,305.00 Closed Level:Federal

Investigators:Schultz, Jo El 01-01-2002 -12-31-2005 American Heart Association - National Chapter Role of Fibroblast Growth Factor-2 Isoforms in the Acute Phase of Cardioprotection in Gene-modified Mouse Models Role:PI $260,050.00 Closed Level:Private Non-Profit

Investigators:Schultz, Jo El 01-01-2002 -12-31-2003 Pharmaceutical Research and Manufacturers of America Role of Protein Kinases in Fibroblast Growth Factor-2-Induced Cardioprotection Role:PI $60,000.00 Closed Level:Industry

Grant: #R21 DA020804 Investigators:Bolte, Craig; Newman, Gilbert; Porter, Darius; Schultz, Jo El 03-01-2008 -02-28-2011 National Institute on Drug Abuse Opioidergic System in Development of Heart Failure Role:PI $402,488.00 Closed Level:Federal

Grant: #2 R56 HL075633-05A1 Investigators:Schultz, Jo El 09-01-2009 -06-30-2015 National Heart, Lung and Blood Institute Signaling Mechanisms of FGF2-Induced Cardioprotection Role:PI $2,023,463.00 Active Level:Federal

Grant: #1 RC2 ES018765-01 Investigators:Belcher, Scott; Lorenz, John; Schultz, Jo El; Wang, Hongsheng 09-30-2009 -06-30-2013 National Institute of Environmental Health Sciences Defining the Impact of Dietary Bisphenol A on Heart Health in the C57BL/6 Mouse Role:Collaborator $1,428,319.00 Active Level:Federal

Grant: #S10 RR027015 Investigators:Greis, Kenneth; Haffey, Wendy; Schultz, Jo El; Shu, Hongjun 09-07-2010 -09-06-2011 National Center for Research Resources Enhanced Proteomics Capabilities for Quantitation of Proteins with a Triple Quadrupole Mass Spectrometer Role:Collaborator $426,215.00 Closed Level:Federal

Grant: #U24 DK059630 Investigators:Benoit, Stephen; Dalessio, David; Davidson, William; Howles, Philip; Hui, David; Jandacek, Ronald; Obici, Silvana; Schultz, Jo El; Seeley, Randy; Tschoep, Matthias; Tso, Patrick P.W.; Welge, Jeffrey; Woods, Stephen; Woollett, Laura 09-16-2011 -06-30-2016 National Inst of Diabetes and Digestive and Kidney Disease Cincinnati Mouse Metabolic Phenotyping Center Role:Collaborator $1,619,789.00 Active Level:Federal

Grant: #SRS 008437 Investigators:Schultz, Jo El 01-01-2013 -12-31-2015 American Society for Pharmacology and Experimental Therapeutics ASPET SURF Institutional Training Program 2013-2015 Role:PI $9,000.00 Active Level:Private Non-Profit

Grant: #14GRNT20450150 Investigators:Schultz, Jo El 07-01-2014 -06-30-2016 American Heart Association - Great Rivers Affiliate Development of novel FGF therapeutics for acute myocardial infarction Role:PI $77,000.00 Awarded Level:Private Non-Profit

Grant: #Check# Investigators:Schultz, Jo El 06-01-2016 -08-31-2018 American Society for Pharmacology and Experimental Therapeutics ASPET SURF Institutional Training Program 2016-2018 Role:PI $9,000.00 Awarded Level:Private Non-Profit

Grant: #SURF 2019-2021 Investigators:Schultz, Jo El 01-01-2019 -12-31-2019 American Society for Pharmacology and Experimental Therapeutics ASPET SURF Institutional Training Program 2019 - 2021 Role:PI $9,000.00 Awarded Level:Private Non-Profit

Grant: #ASPET Check#55523 Yr1 Investigators:Schultz, Jo El 01-02-2023 -12-31-2025 American Society for Pharmacology and Experimental Therapeutics ASPET SURF Institutional Training Program Role:PI 0.00 Awarded Level:Non Profit

Grant: #24PRE1196559 01-01-2024 -12-31-2025 American Heart Association - National Chapter Chromatin remodeling control of vascular integrity in the Central Nervous System Role:PI 33694.00 Awarded Level:Non Profit

Grant: #24PRE1196559 01-01-2024 -12-31-2025 American Heart Association - National Chapter Chromatin remodeling control of vascular integrity in the Central Nervous System Role:PI 33694.00 Awarded Level:Non Profit

Published Abstracts

Smart SC, Schultz J, Sagar KB, Warltier DC (1993. ) Intracoronary doxorubicin, but not intracoronary verapamil, improves recovery of postischemic function .[Abstract]J Am Coll Cardiol, 21 ,164A

Smart SC, Schultz J, Sagar KB, Warltier DC (1993. ) Vasodilation alone does not account for the improved postischemic myocardial function following treatment with intracoronary amiloride .[Abstract]Clin Res, 41 (2 ) ,228A

Smart SC, Schultz J, Sagar KB, Warltier DC (1993. ) Is amiloride the vasodilator of choice for syndromes of acute ischemia and reperfusion? .[Abstract]Clin Res, 41 (3 ) ,642A

Smart SC, Schultz J, Sagar KB, Warltier DC (1993. ) Doxorubicin is the calcium transport antagonist of choice for preventing reperfusion ventricular fibrillation .[Abstract]Clin Res, 41 (3 ) ,684A

Smart SC, Schultz J, LoCurto A, Sagar KB, Warltier DC (1994. ) Inhibition of Na/H exchange is not the mechanism by which amiloride improves postischemic function in open chest dogs .[Abstract]J Am Coll Cardiol (Special Issue), 297A

Smart SC, Schultz J, LoCurto A, Sagar KB, Warltier DC (1994. ) High dose nifedipine, but not high dose verapamil, prevents postischemic myocardial dysfunction in open chest dogs .[Abstract]Clin Res, 42 (2 ) ,162A

Schultz JJ, Yao Z, Gross GJ (1994. ) Evidence for the involvement of opioid receptors in ischemic preconditioning in the rat heart .[Abstract]Circulation, 90 (4 ) ,I-476

Eells JT, Flaig AM, Schultz JJ, Salzman JJ (1995. ) Methanol toxicity: species differences in retinal formate oxidation .[Abstract]Society for Neuroscience Abstracts, 21 ,1741

Gumina RJ, Schultz J, Yao Z, Kenny D, Warltier DC, Gross GJ, Newman PJ (1995. ) Characterization of rat PECAM-1 and demonstration that antibody to PECAM-1 reduces myocardial infarct size .[Abstract]J Invest Med, 43 (Suppl 3 ) ,451A

Schultz JJ, Hsu A, Gross GJ (1996. ) Morphine-induced cardioprotection is mediated via the ATP-sensitive potassium (KATP) channel in the rat heart .[Abstract]FASEB J, 10 (3 ) ,68

Gross GJ, Schultz JJ (1996. ) Glibenclamide abolishes ischemic preconditioning in a time-dependent manner in the rat heart .[Abstract]FASEB J, 10 (3 ) ,809

Schultz JJ, Hsu AK, Gross GJ (1996. ) Delta opioid receptors appear to mediate ischemic- or morphine-induced preconditioning in the intact rat heart .[Abstract]Circulation, 90 (8 ) ,I-364

Schultz JJ, Hsu AK, Nagase H, Gross GJ (1997. ) Ischemic preconditioning (PC) in the intact rat heart is mediated by delta1 (1), but not mu () or kappa () opioid receptors .[Abstract]J Mol Cell Cardiol, 29 (6 ) ,A200

Gross GJ, Mizumura T, Beier N, Schultz JJ (1997. ) A new Na+-H+ exchange (NHE) inhibitor, EMD 85131, limits infarct size in dogs when administered prior to or after coronary occlusion .[Abstract]J Mol Cell Cardiol, 29 (6 ) ,A196

Schultz JJ, Hsu AK, Gross GJ (1997. ) Gi/o proteins are involved in the cardioprotective effect of ischemic preconditioning (PC) in the intact rat .[Abstract]Circulation, 96 (8 ) ,I-574

Gross GJ, Mizumura T, Schultz JJ (1997. ) A new sodium-hydrogen exchange (NHE) inhibitor, EMD 85131, limits infarct size (IS) in dogs independent of adenosine (Ado) or ATP-sensitive potassium (KATP) channels .[Abstract]Circulation, 96 (8 ) ,I-140

Gross GJ, Schultz JJ (1997. ) In dogs tolerant to ischemic preconditioning (IPC), the sodium-hydrogen exchange (NHE) inhibitor, EMD 85131 (EMD), retains its efficacy to reduce myocardial infarct size (IS) .[Abstract]Circulation, 96 (8 ) ,I-743

Gross GJ, Hsu AK, Schultz JJ (1998. ) ATP-sensitive potassium (KATP) channels and Gi/o proteins mediate the cardioprotection afforded by delta-1 (1) opioid receptor stimulation in the intact rat .[Abstract]FASEB Journal, 12 (5 ) ,A1113

Fryer R, Schultz J, Hsu A, Gross G (1998. ) Tyrosine kinase is involved in the initiation of ischemic preconditioning in rats .[Abstract]FASEB J, 12 (4 ) ,A77

Sutliff RL, Paul RJ, Zhou M, Hoying JB, Schultz J, Doetschman T (1998. ) FGF2 isoform specificity in vascular tone control .[Abstract]Weinstein Cardiovascular Development Conference,

Fryer R, Schultz J, Hsu A, Gross GJ (1998. ) Combined inhibition of tyrosine kinase (TK) and protein kinase C (PKC) are necessary to totally abolish ischemic preconditioning (IPC) in rat hearts .[Abstract]Circulation, 98 (17 ) ,I-585

Schultz JJ, Witt SA, Nieman M, Engle SJ, Lorenz JN, Kimball TR, Doetschman T (1999. ) Basic fibroblast growth factor in a pressure overload mouse model of cardiac hypertrophy .[Abstract]Weinstein Cardiovascular Development Conference,

Schultz JJ, Witt SA, Nieman ML, Engle SJ, Lorenz JN, Kimball TR, Doetschman T (1999. ) Fibroblast growth factor-2 involvement in the hypertrophic response to pressure overload in mouse .[Abstract]Circulation, 100 (18 ) ,I-52

Schultz JJ, Witt SA, Ormsby I, Lorenz JN, Kimball TR, Doetschman T (1999. ) Role of TGFb1 in aspects of cardiac hypertrophy in the mouse .[Abstract]Molecular Basis of Heart Disease Meeting,

Witt SA, Schultz JJ, Doetschman TC, Kimball TR (2000. ) The impact of a novel imaging transducer in the assessment of a pressure overload mouse model of cardiac hypertrophy .[Abstract]J Am Coll Cardiol, 352 (2 ) ,472A

Witt SA, Schultz JJ, Lorenz J, Doetschman TC, Kimball TR (2000. ) Invasive validation of in vivo echocardiographic indices of pressure gradients in a murine model .[Abstract]J Am Soc Echo, 13 (5 ) ,466

Witt SA, Schultz JJ, Lorenz J, Doetschman TC, Kimball TR (2000. ) Invasive validation of in vivo echocardiographic indices of pressure gradients in a murine model .[Abstract]J Mol Cell Cardiol, 32 (5 ) ,A37

Flaherty MP, Takano H, Murphree SS, Grupp I, Schultz J, Jones WK (2000. ) Hypertensive-cardiac hypertrophy and induction of molecular markers in eNOS knockout mice .[Abstract]J Mol Cell Cardiol, 32 (5 ) ,A57

Schultz J, Witt SA, Glascock BJ, Lorenz J, Kimball TR, Doetschman T (2000. ) Transforming growth factor 1 (TGF1) in a murine model of cardiac hypertrophy .[Abstract]J Mol Cell Cardiol, 32 (5 ) ,A60

Schultz JJ, Liu LH, Witt SA, Glascock BJ, Kimball TR, Shull GE, Periasamy M (2000. ) Accelerated onset of heart failure during pressure overload in mice with chronically decreased SERCA2 calcium pump activity .[Abstract]Circulation , 100 (18 ) ,I52

Schultz JJ, Grupp IL, Millard RW (2001. ) Utilizing the isolated mammalian heart for evaluations of novel candidate drug beneficial and adverse events .[Abstract]Safety Pharmacology meeting,

Schultz JJ, Klevitsky R, Jakes H, Doetschman T, Newman G (2002. ) Cardioprotective role of FGF2 in a murine model of low-flow ischemia .[Abstract]J Mol Cell Cardiol, 34 (7 ) ,A37

Flaherty MP, Brown M, Takano H, el Schultz J, Murphree S, and Jones WK (2002. ) Compensated cardiac hypertrophy in eNOS knockout mice .[Abstract]J Am Coll Cardiol, 39 (5 ) ,131A

Dostanic I, Lorenz J, Grupp IL, Schultz JJ, Neumann JC, Lingrel JB (2003. ) Inotropic effect of ouabain is mediated through the 2 Na,K-ATPase in heart .[Abstract]FASEB J, 17 (5 ) ,A1323

Liao S, Newman G, Doetschman T, Schultz JJ (2003. ) Evidence for the low molecular weight isoform of fibroblast growth factor-2 to protect against ischemia-reperfusion injury .[Abstract]Molecular mechanisms of growth, death, and regeneration in the myocardium: basic biology and insights into ischemic heart disease and heart failure, American Heart Association meeting,

House SL, Newman G, Doetschman T, Schultz JJ (2003. ) Cardiac-specific overexpression of FGF2 is cardioprotective via a protein kinase C-dependent pathway in a murine model of global low-flow ischemia .[Abstract]Molecular mechanisms of growth, death, and regeneration in the myocardium: basic biology and insights into ischemic heart disease and heart failure, American Heart Association meeting,

Liao S, Newman G, Doetschman T, Schultz JJ (2003. ) Evidence for the low molecular weight isoform of fibroblast growth factor-2 to protect against ischemia-reperfusion injury .[Abstract]Circulation, 108 (17 ) ,IV-187

House SL, Newman G, Doetschman T, Schultz JJ (2004. ) Role of ERK and p38 in cardioprotection induced by overexpression of fibroblast growth factor 2 in the heart .[Abstract]J Mol Cell Cardiol, 36 ,626

Bolte C, Newman G, el Schultz J (2004. ) Evidence for the involvement of the opioidergic system in the development of heart failure .[Abstract]J Mol Cell Cardiol, 37 (1 ) ,203

House SL, el Schultz J, Glascock B, Kimball T, Doetschman T (2004. ) Fibroblast growth factor 2 mediates cardiac hypertrophy induced by isoproterenol through specific MAPK and PKC pathways .[Abstract]J Mol Cell Cardiol, 37 (1 ) ,299

Pathak A, del Monte F, Zhao W, Carr A, Schultz J, Hahn H, Syed F, Mareez Y, DePaoli-Roach A, Hajjar R, Kranias EG (2004. ) Therapeutic targeting of the type 1 phosphatase activity in murine models of cardiomyopathy .[Abstract]Circulation, 110 (17 ) ,I-22

Liao S, Porter D, Newman G, Doetschman T, Schultz JJ (2005. ) Cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling .[Abstract]Circulation, 112 (17 ) ,II-252

Porter D, House S, Newman G, Schultz JJ (2006. ) Evidence for a role in nitric oxide signaling in fibroblast growth factor-2-induced cardioprotection .[Abstract]Gordon Research Conference on Fibroblast Growth Factors in Development and Disease,

Bolte CS, Newman G, Schultz J (2006. ) The role of the opioidergic system in a familial model of dilated cardiomyopathy .[Abstract]FASEB J, 20 ,C99

Liao S, Newman G, Doetschman T, Schultz J El J (2007. ) Role of high molecular weight isoforms of fibroblast growth factor-2 (FGF-2) in cardiac ischemia-reperfusion injury (I/R) .[Abstract]J Mol Cell Cardiol, 42 ,S198

Carpenter G, Porter D, Liao S, Newman G, Schultz J El J (2007. ) Inducible nitric oxide synthase (iNOS), not neuronal NOS (nNOS) in cardioprotection by fibroblast growth factor-2 (FGF-2) .[Abstract]J Mol Cell Cardiol , 42 ,S187

Ren X, Liao S, Schultz JJ, Brown M, Jones WK (2007. ) PKCe mediates nonischemic preconditioning-dependent bradykinin-2 receptor signaling .[Abstract]Cardiovascular repair and regeneration: structural and molecular approaches in the cellular era, American Heart Association meeting,

Pietras DA, Newman G, Schultz JelJ (2008. ) KATP channels are important downstream targets of FGF2-initiated cardioprotective signaling in mice .[Abstract]FASEB J ,

Peer Reviewed Publications

Schultz JE, Rose E, Yao Z, Gross GJ (1995. ) Evidence for the involvement of opioid receptors in ischemic preconditioning in the rat heart .Am J Physiol, , 268 ,H2157-H2161

Smart SC, LoCurto A, el Schultz J, Sagar KB, Warltier DC (1995. ) Intracoronary amiloride prevents contractile dysfunction of postischemic “stunned” myocardium: role of hemodynamic alterations and inhibition of Na+/H+ exchange and L-type Ca2+ channels .J Am Coll Cardiol, , 26 (5 ) ,1365-1373

Schultz JE, Hsu AK, Gross GJ (1996. ) Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart .Circ Res, , 78 ,1100-1104

Gumina RJ, el Schultz J, Yao Z, Kenny D, Warltier DC, Newman PJ, Gross GJ (1996. ) Antibody to Platelet/Endothelial Cell Adhesion Molecule-1 reduces myocardial infarct size in a rat model of ischemia/reperfusion injury .Circulation, , 94 ,3327-3333

Schultz JE, Qian YZ, Gross GJ, Kukreja RC (1997. ) The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks the ischemic preconditioning in the rat heart .J Mol Cell Cardiol, , 29 ,1055-1060

Schultz JJ, Hsu AK, Gross GJ (1997. ) Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart .J Mol Cell Cardiol, , 29 ,1355-1362

Schultz JE, Yao Z, Cavero I, Gross GJ (1997. ) Glibenclamide abolishes ischemic preconditioning in a time-dependent manner in the rat heart .Am J Physiol, , 272 ,H2607-H2615

Schultz JJ, Hsu AK, Gross GJ (1997. ) Ischemic preconditioning and morphine-induced cardioprotection involve the delta ()-opioid receptor in the intact rat heart .J Mol Cell Cardiol, , 29 ,2187-2195

Smart SC, Sagar KB, el Schultz J, Warltier DC, Jones LR (1997. ) Injury to the Ca2+ ATPase of the sarcoplasmic reticulum in anesthetized dogs contributes to myocardial reperfusion injury .Cardiovasc Res, , 36 ,174-184

Schultz J el-J, Hsu AK, Nagase H, Gross GJ (1998. ) TAN-67, a selective delta-1 (1) opioid receptor agonist, reduces myocardial infarct size via activation of Gi/o proteins and KATP channels .Am J Physiol, , 274 ,H909-H914

Schultz JE, Hsu AK, Gross GJ (1998. ) Ischemic preconditioning (PC) in the intact rat heart is mediated by delta1 (1), but not mu () or kappa () opioid receptors .Circulation, , 97 ,1282-1289

Gumina RJ, Mizumura T, Beier N, Schelling P, Schultz JJ, Gross GJ (1998. ) A new sodium/hydrogen exchanger inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion .J Pharmacol Exp Therap, , 286 (1 ) ,175-183

Schultz JE, Hsu AK, Barbieri JT, Li P-L, Gross GJ (1998. ) Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in the intact rat heart .Am J Physiol, , 275 ,H495-H500

Schultz JE, Hsu AK, Kwok W-M, Gross GJ (1998. ) Terikalant, the inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat .J Mol Cell Cardiol, , 30 ,1817-1825

Fryer RM, Schultz JE, Hsu AK, Gross GJ (1998. ) Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in the rat heart .Am J Physiol, , 275 ,H2009-H2015

Fryer R, Schultz JE, Hsu A, Gross G (1999. ) Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts .Am J Physiol, , 276 ,H1229-H1235

Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, Pawlowski SA, Lorenz JN, Kimball TR, Doetschman T (1999. ) Fibroblast growth factor-2 mediates pressure-induced hypertrophic response (featured on cover) .J Clin Invest, , 104 ,709-719

Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix S, Kimball TR, Doetschman T (2002. ) Transforming growth factor-1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II (see commentary: Schneider MD. Serial killer: angiotensin drives cardiac hypertrophy via TGF-1 .J Clin Invest, , 109 ,715-716

Maslov LN, Lishmanov YB, Gross GJ, Schultz JE, Stefano G (2002. ) Opioid receptor activation alters cardiac tolerance to ischemic and reperfusion damages .Vestnik Arrhythmologyi (Russian), , N28 ,67-78

House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, Schultz Jel J (2003. ) Cardiac-specific overexpression of fibroblast growth factor-2 (FGF2) protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia .Circulation, , 108 ,3140-3148

Dostanic I, Lorenz JN, Schultz Jel J, Grupp IL, Neumann JC, Lingrel JB (2003. ) Increase in cardiac contractility by low concentrations of ouabain is mediated through the 2 NA,K-ATPase isozyme .J Biol Chem, , 278 (52 ) ,53026-53034

Schultz Jel J, Glascock BJ, Witt SA, Nieman ML, Nattami KJ, Liu LH, Lorenz JN, Shull GE, Kimball TR, Periasamy M (2004. ) Accelerated onset of heart failure during pressure overload in mice with chronically decreased SERCA2 calcium pump activity .Am J Physiol, , 286 ,H1146-1153

Moseley AE, Cougnon MH, Grupp IL, El Schultz J, Lingrel JB (2004. ) Attenuation of cardiac contractility in Na,K-ATPase 1 isoform-deficient hearts under reduced calcium conditions .J Mol Cell Cardiol, , 37 (5 ) ,913-919

Dostanic I, Schultz Jel J, Lorenz JN, Lingrel JB (2004. ) The 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca-exchanger in heart .J Biol Chem, , 279 (52 ) ,54053-54061

Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Mareez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG (2005. ) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1 .Circ Res, , 96 (7 ) ,756-766

House SL, Branch K, Newman G, Doetschman T, Schultz Jel J (2005. ) Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade .Am J Physiol, , 289 (5 ) ,H2167-2175

Gumina RJ, El Schultz J, Moore J, Beier N, Schelling P, Gross GJ (2005. ) Cardioprotective-mimetics reduce myocardial infarct size in animals resistant to ischemic preconditioning .Cardiovasc Drugs Ther, , 19 (5 ) ,315-22

Ji Y, Zhao W, Kaetzel M, Li B, Schultz Jel J, Kranias E, Bers DM, Dedman JR (2006. ) Targeted inhibition of sarcoplasmic reticulum CaMKII activity results in alterations of Ca2+ homeostasis and cardiac contractility .Am J Physiol, , 290 (2 ) ,H599-606

Zhao W, Yuan Q, Pathak A, Chu G, Mitton B, Waggoner J, Qian J, Sun X, Jin J, Braz JC, Hahn HS, Marreez Y, Syed F, Pollesello P, Annila A, Brown KM, Wang H, Schultz Jel J, Molkentin JG, Liggett SB, Dorn II GW, Kranias EG (2006. ) The presence of Lys27 instead of Asn27 in human phospholamban promotes SERCA2 superinhibition and cardiac remodeling .Circulation, , 113 (7 ) ,995-1004

House SL, Melhorn S, Newman G, Doetschman T, Schultz Jel J (2007. ) Cardiac-specific overexpression of FGF2 is cardioprotective via a protein kinase C-dependent pathway in a murine model of global low-flow ischemia .Am J Physiol, , 293 (1 ) ,H354-65

Flaherty M, Brown M, Grupp I, Schultz J, Murphree S, Jones WK (2007. ) eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression .Cardiovasc Tox, , 7 (3 ) ,165-77

Bolte, Craig; Newman, Gilbert; Schultz, Jo El J (2009. ) Kappa and delta opioid receptor signaling is augmented in the failing heart.Journal of molecular and cellular cardiology, , 47 (4 ) ,493-503 More Information

Bolte, Craig; Newman, Gilbert; Schultz, Jo El J (2009. ) Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation.American journal of physiology. Heart and circulatory physiology, , 296 (4 ) ,H967-75 More Information

Jones, W Keith; Fan, Guo-Chang; Liao, Siyun; Zhang, Jun-Ming; Wang, Yang; Weintraub, Neal L; Kranias, Evangelia G; Schultz, Jo El; Lorenz, John; Ren, Xiaoping (2009. ) Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling.Circulation, , 120 (11 Suppl ) ,S1-9 More Information

Liao, Siyun; Porter, Darius; Scott, Alana; Newman, Gilbert; Doetschman, Thomas; Schultz, Jo El J (2007. ) The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling.Journal of molecular and cellular cardiology, , 42 (1 ) ,106-20 More Information

Liao, Siyun; Bodmer, Janet R; Azhar, Mohamad; Newman, Gilbert; Coffin, J Douglas; Doetschman, Thomas; Schultz, Jo El J (2010. ) The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury.Journal of molecular and cellular cardiology, , 48 (6 ) ,1245-54 More Information

Manning, Janet R; Carpenter, Gregory; Porter, Darius R; House, Stacey L; Pietras, Daniel A; Doetschman, Thomas; Schultz, Jo el J (2012. ) Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.Growth factors (Chur, Switzerland), , 30 (2 ) ,124-39 More Information

House, Stacey L; House, Brian E; Glascock, Betty; Kimball, Thomas; Nusayr, Eyad; Schultz, Jo El J; Doetschman, Thomas (2010. ) Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.Molecular and cellular pharmacology, , 2 (4 ) ,143-154 More Information

Schultz, J E; Witt, S A; Nieman, M L; Reiser, P J; Engle, S J; Zhou, M; Pawlowski, S A; Lorenz, J N; Kimball, T R; Doetschman, T (1999. ) Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.The Journal of clinical investigation, , 104 (6 ) ,709-19 More Information

Wijeratne, Aruna B; Manning, Janet R; Schultz, Jo El J; Greis, Kenneth D (2013. ) Quantitative phosphoproteomics using acetone-based Peptide labeling: method evaluation and application to a cardiac ischemia/reperfusion model.Journal of proteome research, , 12 (10 ) ,4268-79 More Information

Manning, Janet R; Perkins, Sarah O; Sinclair, Elizabeth A; Gao, Xiaoqian; Zhang, Yu; Newman, Gilbert; Pyle, W Glen; Schultz, Jo El J (2013. ) Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction.American journal of physiology. Heart and circulatory physiology, , 304 (10 ) ,H1382-96 More Information

Schulz, Emily M; Correll, Richard N; Sheikh, Hajer N; Lofrano-Alves, Marco S; Engel, Patti L; Newman, Gilbert; Schultz, Jo El J; Molkentin, Jeffery D; Wolska, Beata M; Solaro, R John; Wieczorek, David F (2012. ) Tropomyosin dephosphorylation results in compensated cardiac hypertrophy.The Journal of biological chemistry, , 287 (53 ) ,44478-89 More Information

Bolte, Craig; Zhang, Yufang; York, Allen; Kalin, Tanya V; Schultz, Jo El J; Molkentin, Jeffery D; Kalinichenko, Vladimir V (2012. ) Postnatal ablation of Foxm1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling.PloS one, , 7 (11 ) ,e48713 More Information

Zhao, Wen; Yuan, Qunying; Qian, Jiang; Waggoner, Jason R; Pathak, Anand; Chu, Guoxiang; Mitton, Bryan; Sun, Xiaoyin; Jin, Jay; Braz, Julian C; Hahn, Harvey S; Marreez, Yehia; Syed, Faisal; Pollesello, Piero; Annila, Arto; Wang, Hong-Sheng; Schultz, Jo El J; Molkentin, Jeffery D; Liggett, Stephen B; Dorn, Gerald W; Kranias, Evangelia G (2006. ) The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling.Circulation, , 113 (7 ) ,995-1004 More Information

Ji, Yong; Zhao, Wen; Li, Bailing; Desantiago, Jaime; Picht, Eckard; Kaetzel, Marcia A; Schultz, Jo El J; Kranias, Evangelia G; Bers, Donald M; Dedman, John R (2006. ) Targeted inhibition of sarcoplasmic reticulum CaMKII activity results in alterations of Ca2+ homeostasis and cardiac contractility.American journal of physiology. Heart and circulatory physiology, , 290 (2 ) ,H599-606 More Information

Dostanic, Iva; Schultz, Jo El J; Lorenz, John N; Lingrel, Jerry B (2004. ) The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart.The Journal of biological chemistry, , 279 (52 ) ,54053-61 More Information

Schultz, Jo El J; Glascock, Betty J; Witt, Sandra A; Nieman, Michelle L; Nattamai, Kalpana J; Liu, Lynne H; Lorenz, John N; Shull, Gary E; Kimball, Thomas R; Periasamy, Muthu (2004. ) Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity.American journal of physiology. Heart and circulatory physiology, , 286 (3 ) ,H1146-53 More Information

Dostanic, Iva; Lorenz, John N; Schultz, Jo El J; Grupp, Ingrid L; Neumann, Jonathan C; Wani, Maqsood A; Lingrel, Jerry B (2003. ) The alpha2 isoform of Na,K-ATPase mediates ouabain-induced cardiac inotropy in mice.The Journal of biological chemistry, , 278 (52 ) ,53026-34 More Information

Azhar, Mohamad; Schultz, Jo El J; Grupp, Ingrid; Dorn, Gerald W; Meneton, Pierre; Molin, Daniel G M; Gittenberger-de Groot, Adriana C; Doetschman, Thomas (2003. ) Transforming growth factor beta in cardiovascular development and function. Cytokine & growth factor reviews, , 14 (5 ) ,391-407

Schultz, Jo El J; Witt, Sandra A; Glascock, Betty J; Nieman, Michelle L; Reiser, Peter J; Nix, Stacey L; Kimball, Thomas R; Doetschman, Thomas (2002. ) TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.The Journal of clinical investigation, , 109 (6 ) ,787-96 More Information

Invited Publications

Gross GJ, Mei DA, Schultz JJ, Mizumura T (1996. ) Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? .Basic Res Cardiol, 91 ,31-34

Schultz JE, Gross GJ (2001. ) Opioids and cardioprotection .Pharmacol Ther, 89 (2 ) ,123-137

Azhar M, Schultz Jel J, Grupp I, Gittenberger-de Groot A, Dorn G, Meneton P, Doetschman T (2003. ) Transforming growth factor beta in cardiovascular development and function .Cytokines and Growth Factor Reviews, 14 ,391-407

Bolte CS*, Liao S*, Gross GJ, Schultz Jel J (2007. ) Remote preconditioning-- endocrine targets of organ protection against ischemic injury .Endocrine, Metabolic and Immune Disorders-Drug Targets, 7 ,167-175

Book Chapter

Gross GJ, Schultz JJ (1997 ) Opioid receptors, KATP channels and ischemic preconditioning Adenosine, cardioprotection and its clinical application .(pp. 125-131).Boston, Kluwer Academic Publishers

Grupp IL, Schultz J, Sfyris G, Grupp G (2001 ) The isolated work-performing and ejecting mouse heart preparation: comparison and quantification of cardiac performance in transgenic and wild-type mice Cardiovascular physiology in the genetically engineered mouse, 2nd ed. (pp. 129-150).

Schultz JJ, Hoying JB, Sullivan C, Doetschman T (2002 ) FGF and the cardiovascular system Fibroblast growth factor in the cardiovascular system .(pp. 45-66).Munich, I. Holzapfel Publishers

Gross GJ, Fryer RM, Patel HH, Schultz JJ (2003 ) Cardioprotection and delta opioid receptors The delta receptor .(pp. 451-466).New York, Marcel Dekker Publishers

Invited Presentations

(2006. ) “Fibroblast growth factor-2 in ischemia-reperfusion injury” .Federation of American Societies for Experimental Biology meeting, San Francisco, CA.

(2006. ) Poster Presentation .Gordon Research Conference on Fibroblast Growth Factors in Development and Disease, Ventura, CA.

(2005. ) Oral Presentation and Poster Presentation .American Heart Association meeting, Dallas, TX.

(2002. ) Poster Presentation .International Society for Heart Research meeting, Madison, WI.

(2000. ) Oral Presentation .American Heart Association meeting, New Orleans, LA.

(2000. ) Poster Presentation .International Society for Heart Research meeting, Louisville, KY.

(1999. ) Oral Presentation .Molecular Basis of Heart Disease meeting, Paris, France.

(1999. ) Oral Presentation .American Heart Association meeting, Atlanta, GA.

(1999. ) Oral Presentation .Weinstein Cardiovascular Development Conference, Tucson, AZ.

(1997. ) Oral Presentation .American Heart Association meeting, Orlando, FL.

(1997. ) Poster Presentation .International Society for Heart Research meeting, Vancouver, British Columbia, Canada.

(1996. ) Poster Presentation .American Heart Association meeting, New Orleans, LA.

(1996. ) Oral Presentation .Experimental Biology ’96 meeting, Washington, D. C..

(1996. ) Poster Presentation .Experimental Biology ’96 meeting, Washington, D. C..

(1994. ) Poster Presentation .American Heart Association meeting, Dallas, TX.

(2007. ) “Role of fibroblast growth factor-2 in ischemia-reperfusion injury and cardioprotection” .Department of Pharmaceutical Sciences Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI.

(2007. ) “Evidence for the opioidergic system in the pathology of heart failure” .Department of Molecular and Cellular Physiology University of Cincinnati, College of Medicine , Cincinnati, OH.

Dr. J. Schultz, Dr. L. Waggoner, Dr. W. Merrill (2006. ) “Angiogenesis factor to treat end-stage coronary artery disease” .Department of Internal Medicine University of Cincinnati, College of Medicine , Cincinnati, OH.

(2005. ) “Role of fibroblast growth factor-2 in ischemia-reperfusion injury and cardioprotection” .Department of Internal Medicine, Division of Nephrology University of Cincinnati, College of Medicine , Cincinnati, OH.

(2004. ) “Role of fibroblast growth factor-2 in protecting the heart against ischemia-reperfusion injury” .Department of Pharmacology and Toxicology Medical College of Wisconsin , Milwaukee, WI.

2008 Nominated for the George Barbour Award for Good Faculty-Student Relations University of Cincinnati Cincinnati, OH

2007 Recipient, Ohio Bioscience 30 in Their 30s Award BioOhio: Accelerating Biosciences in Ohio

2006 Nominated for Sigma Xi Research Award University of Cincinnati Cincinnati, OH

2004 Recipient, 40 Under 40 Award University of Cincinnati, College of Medicine Cincinnati, OH

2002 Recipient, Best Abstract Award International Society of Heart Research Meeting, American Section Madison, WI

2002 Recipient, PhRMA Foundation Research Starter Grant Award ASPET 2002 Annual Meeting New Orleans, LA

2000 Recipient, First Annual Albert B. Sabin Award for the most Outstanding Young Biomedical Scientist Sponsored by the Sabin Family and Bio/Start, the biomedical incubator Cincinnati, OH

1998 Recipient, Honorable Mention Second Annual Postdoctoral Scholar Research Forum University of Cincinnati, College of Medicine Cincinnati, OH

1996 Recipient, MCW Phonathon Student Travel Award

1996 Recipient, ASPET Student Travel Award

1996 -1997 Recipient, two year Advanced Predoctoral Fellowship Pharmaceutical Research and Manufacturers of America, Inc. Foundation

1994 Recipient, MCW Phonathon Student Travel Award

Stacey House (nee Nix), Ph.D. Supervisor Status:Completed 10-2005

Siyun Liao, Ph.D. Supervisor Status:Completed 02-2008

Craig Bolte, Ph.D. candidate Supervisor Status:In Progress

Daniel Pietras, Ph.D. candidate Supervisor Status:In Progress

Janet Bodmer, Ph.D. candidate Supervisor Status:In Progress

Kimberly Gregory Ph.D. Committee Member Status:Completed 05-2005

Anand Pathak, Ph.D. Committee Member Status:Completed 02-2006

Maria Brown Committee Member Status:In Progress

Jian Xu Committee Member Status:Completed 05-2006

Qunying Yuan, Ph.D. Committee Member Status:Completed 05-2007

Michael Wilhide Committee Member Status:In Progress

Jiang Qian Committee Member Status:In Progress

Persoulla Nicolaou Committee Member Status:In Progress

Melissa Stropes Committee Member Status:In Progress

Elaine Shelton, Ph.D. Committee Member Status:Completed 12-2007

Katrina Paumier Committee Member Status:In Progress

Eric Gross Committee Member Status:Completed 03-2005

Chereasa Williams Supervisor Status:Completed 03-2006

Megan Strouth Supervisor

Cardioprotection and Ischemia-reperfusion Injury,Cardiac Hypertrophy and Heart Failure,Signaling Mechanisms

11-2006 -To Present: Member Institutional Animal Care and Use Committee. The charge of this committee is to review animal use protocols and perform semi-annual inspections of animal facilities (laboratories, surgical suites, housing rooms). University of Cincinnati, Cincinnati, OH

09-2007 -To Present: Member College Core Curriculum Committee The charge of this committee is to review current College of Medicine Graduate School curriculum and make recommendations to the College Graduate Education Committee. University of Cincinnati, College of Medicine, Cincinnati, OH

09-2006 -To Present: Member College Graduate Education Committee. The charge of this committee is to provide oversight of the College of Medicine graduate education program and recommendations regarding curriculum, recruitment, student/faculty policies. University of Cincinnati, College of Medicine, Cincinnati, OH

04-2006 -06-2006: Substitute member for Dr. Rapoport College Graduate Education Committee The charge of this committee is to provide oversight of the College of Medicine graduate education program and recommendations regarding curriculum, recruitment, student/faculty policies. University of Cincinnati, College of Medicine, Cincinnati, OH

05-2006: Participant, Junior Faculty Representative NIH Review of the Physician Scientist Training Program University of Cincinnati, College of Medicine, Cincinnati, OH

11-2004: Participant, Junior Faculty Representative Ohio Board of Regents Review of the Physician Scientist Training Program University of Cincinnati, College of Medicine, Cincinnati, OH

09-2003 -10-2003: Participant, Junior Faculty Representative Liaison Committee on Medical Education (LCME) Self-Study Task Force University of Cincinnati, College of Medicine, Cincinnati, OH

07-2003: Participant Ad Hoc Committee on Safety Compliance The charge of this committee is to provide recommendations regarding occupational health and safety policies and monitoring avenues for faculty, staff, and students that come into contact with biohazards, radioactive materials, or animals University of Cincinnati, College of Medicine, Cincinnati, OH

09-2007 -To Present: Member Affiliated Faculty, GEC subcommittee The charge of this committee is to develop criteria for graduate program faculty affiliation, review materials, and provide recommendations to the Departmental GEC. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

09-2006 -To Present: Graduate Program Director Graduate Education Committee. The charge of this committee is to provide oversight of the departmental graduate education program and provide recommendations regarding curriculum, recruitment, student/faculty policies. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

06-2006 -To Present: Member Appointment, Reappointment, Promotion and Tenure (ARPT) Committee. The charge of this committee is to provide initial review of appointment, reappointment, promotion and tenure materials and to evaluate and update departmental ARPT polices. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

11-2002 -To Present: Member Space Committee The charge of this committee is to review and make recommendations regarding departmental wet research space to provide continuity in research functions by faculty during reconstruction and reorganization of Medical Science Building and Cardiovascular Center infrastructure. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

10-2002 -To Present: Departmental Representative Faculty Forum Executive Committee The charge of this position is to be a spokesperson regarding concerns and issues of the Department of Pharmacology faculty and act as a conduit between the Department and other departments as well as the College of Medicine. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

2002 -2004: Member Medical Education Committee The charge of this committee is to provide oversight of the Medical Pharmacology curriculum, establish and review the Medical Pharmacology examination question bank, and provide recommendations to the Director and co-Director of the Medical Pharmacology course. University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

2000 -2005: Task Force Committee member and Director Isolated Work-Performing Heart Facility The charge of this committee is to provide recommendations to the Chairman regarding the operations (fiscal, scientific, and educational) of the isolated heart facility departmental core University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

Invited Speaker Physician Scientist Training Program Seminar Series University of Cincinnati, College of Medicine, Cincinnati, OH

Interviewer Biomedical Sciences Flex Option University of Cincinnati, College of Medicine, Cincinnati, OH

Judge Undergraduate Poster Competition for the NSF REU Site Program in Membrane Applied Science and Technology University of Cincinnati, College of Medicine, Cincinnati, OH

Interviewer Physician Scientist Training Program University of Cincinnati, College of Medicine, Cincinnati, OH

Judge Graduate Student Research Forum University of Cincinnati, College of Medicine, Cincinnati, OH

Invited Speaker Work In Progress (WIPS) Post-doctoral Seminar Series Discussion: “Issues to deciding on working in academics versus industry” and “Starting your own academic lab” University of Cincinnati, College of Medicine, Cincinnati, OH

Faculty Participant University of Cincinnati, College of Medicine, Graduate Recruitment Fair University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

Interviewer Molecular, Cellular, and Biochemical Pharmacology Graduate Program University of Cincinnati, College of Medicine, Department of Pharmacology and Cell Biophysics, Cincinnati, OH

Invited Speaker University of California-Santa Barbara Pharmacology Undergraduate Program “Getting a PhD in Pharmacology” University of California-Santa Barbara, Santa Barbara, CA

06-2008: Co-chair Cardiac Signaling Symposium International Society for Heart Research, North American Section, Cincinnati, OH

Member American Society of Pharmacology and Experimental Therapeutics

Member Basic Cardiovascular Sciences Scientific Council of the American Heart Association

Member International Society for Heart Research

Member Heart Failure Society of America

Member American Physiological Society

03-2008: Grant Reviewer NRSA Study Section, Physiology and Pathobiology of Organ Systems National Institutes of Health

02-2006: Grant Reviewer Myocardial Ischemia and Metabolism Study Section National Institutes of Health, Heart Lung and Blood Institute

11-2005: Grant Reviewer Medical Research Council United Kingdom

08-2005: Grant Reviewer Pilot/Feasibility Grant Program Michigan Diabetes Research and Training Center

12-2004: Grant Reviewer Special Emphasis Panel, Electrical Signaling, Ion Transport and Arrhythmias (ESTA) Study Section National Institutes of Health, Heart Lung and Blood Institute

11-2004: Grant Reviewer Appeal for Reconsideration of VA Merit Award

04-2003: Grant Reviewer Academia Europea Prizes of Academia for young Russian scientists Moscow, Russia

2002 -To Present: Grant Reviewer Research Grants Council Hong Kong, China

04-2008: Abstract Reviewer Autonomic, Reflex, and Neurohormonal Control of Circulation (BCVS) category American Heart Association Scientific Sessions

2004 -2007: Grant Reviewer American Heart Association Southern and Ohio Valley Research Consortium

2007: Abstract Reviewer Autonomic, Reflex, and Neurohormonal Control of Circulation (BCVS) category American Heart Association Scientific Sessions

Medical Pharmacology

Special Topics in Pharmacology: (Neuro)Endocrine Pharmacology

Special Topics in Pharmacology: Pharmacogenomics- search for individualized medicine

Molecular and Cellular Pharmacology

Receptor Pharmacology

Graduate Physiology II (Cardiovascular Physiology)

Integrative Therapies for Health Sciences

Pharmacology for Advanced Practice Nurses